MRC Epidemiology Unit, Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Diabetologia. 2022 Mar;65(3):424-439. doi: 10.1007/s00125-021-05605-1. Epub 2021 Dec 2.
AIMS/HYPOTHESIS: Weight loss is often recommended in the treatment of type 2 diabetes. While evidence has shown that large weight loss may lead to diabetes remission and improvement in cardiovascular risk factors, long-term impacts are unclear. We performed a systematic review of studies of weight loss and other weight changes and incidence of CVD among people with type 2 diabetes.
Observational studies of behavioural (non-surgical and non-pharmaceutical) weight changes and CVD events among adults with type 2 diabetes, and trials of behavioural interventions targeting weight loss, were identified through searches of MEDLINE, EMBASE, Web of Science, CINAHL, and The Cochrane Library (CENTRAL) until 9 July 2019. Included studies reported change in weight and CVD and/or mortality outcomes among adults with type 2 diabetes. We performed a narrative synthesis of observational studies and meta-analysis of trial data.
Of 13,227 identified articles, 17 (14 observational studies, three trials) met inclusion criteria. Weight gain (vs no change) was associated with higher hazard of CVD events (HRs [95% CIs] ranged from 1.13 [1.00, 1.29] to 1.63 [1.11, 2.39]) and all-cause mortality (HRs [95% CIs] ranged from 1.26 [1.12, 1.41] to 1.57 [1.33, 1.85]). Unintentional weight loss (vs no change) was associated with higher risks of all-cause mortality, but associations with intentional weight loss were unclear. Behavioural interventions targeting weight loss showed no effect on CVD events (pooled HR [95% CI] 0.95 [0.71, 1.27]; I = 50.1%). Risk of bias was moderate in most studies and was high in three studies, due to potential uncontrolled confounding and method of weight assessment.
CONCLUSIONS/INTERPRETATION: Weight gain is associated with increased risks of CVD and mortality, although there is a lack of data supporting behavioural weight-loss interventions for CVD prevention among adults with type 2 diabetes. Long-term follow-up of behavioural intervention studies is needed to understand effects on CVD and mortality and to inform policy concerning weight management advice and support for people with diabetes. PROSPERO registration CRD42019127304.
目的/假设:在治疗 2 型糖尿病时,常建议减轻体重。虽然有证据表明,大量减轻体重可能导致糖尿病缓解和心血管风险因素改善,但长期影响尚不清楚。我们对 2 型糖尿病患者的体重减轻和其他体重变化以及心血管疾病(CVD)发生率的研究进行了系统评价。
通过对 MEDLINE、EMBASE、Web of Science、CINAHL 和 The Cochrane Library(CENTRAL)的检索,确定了针对 2 型糖尿病成人的行为(非手术和非药物)体重变化和 CVD 事件的观察性研究,以及针对体重减轻的行为干预试验。纳入的研究报告了 2 型糖尿病成人的体重变化和 CVD 及/或死亡率结果。我们对观察性研究进行了叙述性综合分析,并对试验数据进行了荟萃分析。
在 13227 篇鉴定的文章中,有 17 篇(14 项观察性研究,3 项试验)符合纳入标准。体重增加(与无变化相比)与 CVD 事件发生风险更高相关(HR[95%CI]范围为 1.13[1.00,1.29]至 1.63[1.11,2.39])和全因死亡率(HR[95%CI]范围为 1.26[1.12,1.41]至 1.57[1.33,1.85])。非故意体重减轻(与无变化相比)与全因死亡率升高相关,但与故意体重减轻的相关性尚不清楚。针对体重减轻的行为干预措施对 CVD 事件没有影响(合并 HR[95%CI]0.95[0.71,1.27];I=50.1%)。大多数研究的偏倚风险为中度,有 3 项研究的偏倚风险较高,这是由于潜在的无法控制的混杂因素和体重评估方法。
结论/解释:体重增加与 CVD 和死亡率风险增加相关,尽管缺乏支持 2 型糖尿病成人通过行为干预减轻体重预防 CVD 的数据。需要对行为干预研究进行长期随访,以了解对 CVD 和死亡率的影响,并为有关糖尿病患者体重管理建议和支持的政策提供信息。PROSPERO 注册号 CRD42019127304。